Skip to content

SAFRANE

Active Private limited companyfounded 2014active for 11 yearsJules Van Ooststraat 24, 8700 TieltKBO/BCE: BE 0507.715.519

Lifetime

11 annual accounts with figures on one time axis
peak of €523,423 in 2025
€511,869▼ 2.2%
lowest -€28,721 in 2017
€369,804unchanged
peak of €296,825 in 2021
€85,602▼ 0.2%
€671,190▲ 33.5%
peak of 0.5 FTE in 2021
-not published
Board1 name since 2014
1 director
Documentsfilings and deeds
19-07-2026104 days before the deadline
2026micro format
Dividend €370,000Debts from €502,803 to €671,190Cash from €322,205 to €496,235

Key points

from the 2026 annual accounts

Equity

€85,602 from €296,825 in 2021

Equity fell by 71% in 5 years.

Debts

€671,190 89% of the balance sheet
Suppliers 0%Taxes and wages 9%Other 91%

Position in the sector

11.3%

Lower solvency than 88% of companies in human health. The sector median is 71.4%, over 563 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,609 companies had the same profile as SAFRANE has now. Each dot stands for 7 companies, two years later.

96.8%
were still trading
2.1%
stopped another way
1.0%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,609 companies, not a prediction for SAFRANE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 23-12-2014
  • 186 sharesdeed of 29-12-2014
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0507715519
resigns as director reappointed as director · “Het inrichten van algemene diensten en een medisch secretariaat in het bijzonder, die nuttig of nodig zijn…” (deed in Dutch) · General meeting of 12-12-2023 · Gazette deed
Registered office moved from Oeselgem to Aarsele The registered office moved from VAERESTRAAT 17 8720 OESELGEM to Jules Van Ooststraat 24 8700 Aarsele · Board meeting of 28-07-2022 · Gazette deed
Registered office moved from Dentergem to Oeselgem The registered office moved from Groeneweg 25, 8720 Dentergem to Vaerestraat 17, 8720 Oeselgem · General meeting of 06-09-2016 · Gazette deed
All 25 events

Comparable companies

same main activity, similar in size and age
Company
SAFRANE Tielt €756,792 €511,869 11.3% -
BJORSKA Diest €774,184 €514,176 0.1% -
Dr. P. Ruette Berlaar €696,007 €504,113 2.7% -
DR. BART DENYS Internist-Nefroloog Deinze €769,618 €468,749 30.6% -
Dr. Bram Ngo, Klinisch Bioloog Hasselt €874,277 €508,061 87.3% -
MAISON MEDICALE SUR LESSE Houyet €749,725 €445,522 57.6% 5
DOKTER VERMEULEN, OOGARTS Kontich €649,682 €540,494 81.9% -

These companies have the same main activity as SAFRANE: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €650,000 and €874,000, founded between 2013 and 2015.

Official details

Source: KBO
Status
Active since 23-12-2014Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.238.462.9619000 Ghent, since 01-01-2015
Financial year end
31 March
Peppol
Reachable since 27-03-2026
Company details

Annual accounts to 31-03-2026

≈ €770,000estimated
€756,792▲ 28.6%
Filing
Filed on 19-07-2026, 104 days before the end of the filing period
Financials

Insights on SAFRANE

SAFRANE files the micro format. That format states no turnover. The gross margin rose from €125,858 in 2016 to €511,869 in 2026.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about SAFRANE

What is the company number of SAFRANE?
The company number of SAFRANE is 0507.715.519. The VAT number is the same number with BE in front: BE 0507.715.519.
Where is SAFRANE based?
The registered office is at Jules Van Ooststraat 24, 8700 Tielt.Company details
What does SAFRANE do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of SAFRANE?
SAFRANE is a private limited company (BV).
When was SAFRANE founded?
SAFRANE was founded on 23-12-2014.
Is SAFRANE still active?
Yes, SAFRANE is an active enterprise in the KBO register.
How many employees does SAFRANE have?
SAFRANE had an average of 0.8 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
What is the turnover of SAFRANE?
The turnover in financial year 2026 is about €770,000. This figure is estimated from the gross margin of €511,869 and 31 comparable companies (NACE 86220). It probably lies between €680,000 and €1.1m.
Is SAFRANE profitable?
In financial year 2026, SAFRANE made a profit of €369,804.
Where can I find the annual accounts of SAFRANE?
SAFRANE filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
When are the next annual accounts of SAFRANE due?
SAFRANE must file the annual accounts for financial year 2027 by 31-10-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.